

# Vincenzo Mazzaferro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4317462/publications.pdf>

Version: 2024-02-01

334  
papers

66,702  
citations

3531

90  
h-index

751

250  
g-index

336  
all docs

336  
docs citations

336  
times ranked

40459  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sorafenib in Advanced Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 378-390.	27.0	12,004
2	Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis. <i>New England Journal of Medicine</i> , 1996, 334, 693-700.	27.0	6,573
3	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 69, 182-236.	3.7	6,153
4	EASL/EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 908-943.	3.7	5,214
5	Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. <i>Lancet Oncology</i> , The, 2009, 10, 35-43.	10.7	1,920
6	BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. <i>Journal of Hepatology</i> , 2022, 76, 681-693.	3.7	1,495
7	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. <i>Nature Genetics</i> , 2015, 47, 505-511.	21.4	1,372
8	Hepatocellular carcinoma: clinical frontiers and perspectives. <i>Gut</i> , 2014, 63, 844-855.	12.1	1,180
9	Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 1995-2004.	27.0	1,148
10	Resection and Liver Transplantation for Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2005, 25, 181-200.	3.6	1,043
11	Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1344-1354.	10.7	809
12	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. <i>Journal of Hepatology</i> , 2012, 57, 821-829.	3.7	736
13	miR-221 overexpression contributes to liver tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 264-269.	7.1	679
14	Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. <i>Gastroenterology</i> , 2017, 153, 812-826.	1.3	650
15	Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2008, 135, 1972-1983.e11.	1.3	644
16	Immunotherapies for hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 151-172.	27.6	643
17	Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. <i>Hepatology</i> , 2007, 45, 938-947.	7.3	632
18	A Clinical Outcome-Based Prospective Study on Venous Thromboembolism After Cancer Surgery. <i>Annals of Surgery</i> , 2006, 243, 89-95.	4.2	595

#	ARTICLE	IF	CITATIONS
19	Focal Gains of <i>VEGFA</i> and Molecular Classification of Hepatocellular Carcinoma. <i>Cancer Research</i> , 2008, 68, 6779-6788.	0.9	589
20	Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions. <i>Seminars in Liver Disease</i> , 2013, 32, 348-359.	3.6	508
21	Percutaneous Radio-frequency Thermal Ablation of Nonresectable Hepatocellular Carcinoma after Occlusion of Tumor Blood Supply. <i>Radiology</i> , 2000, 217, 119-126.	7.3	490
22	Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis of 15 years of experience. <i>Liver Transplantation</i> , 2011, 17, S44-S57.	2.4	471
23	Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization. <i>Cancer Treatment Reviews</i> , 2011, 37, 212-220.	7.7	460
24	Radiofrequency Ablation of Small Hepatocellular Carcinoma in Cirrhotic Patients Awaiting Liver Transplantation. <i>Annals of Surgery</i> , 2004, 240, 900-909.	4.2	452
25	Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes. <i>Gastroenterology</i> , 2013, 144, 829-840.	1.3	438
26	Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2019, 69, 107-120.	7.3	433
27	Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study. <i>Hepatology</i> , 2013, 57, 1826-1837.	7.3	428
28	Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2018, 154, 128-139.	1.3	417
29	Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2011, 140, 1501-1512.e2.	1.3	389
30	A Molecular Signature to Discriminate Dysplastic Nodules From Early Hepatocellular Carcinoma in HCV Cirrhosis. <i>Gastroenterology</i> , 2006, 131, 1758-1767.	1.3	379
31	DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. <i>Hepatology</i> , 2015, 61, 1945-1956.	7.3	367
32	Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. <i>Journal of Hepatology</i> , 2018, 69, 1284-1293.	3.7	360
33	Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. <i>Hepatology</i> , 2006, 44, 1543-1554.	7.3	347
34	Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma. <i>Transplantation</i> , 2016, 100, 116-125.	1.0	339
35	Resection of hepatocellular cancer $\geq 2$ cm: Results from two Western centers. <i>Hepatology</i> , 2013, 57, 1426-1435.	7.3	326
36	Neuroendocrine tumors metastatic to the liver: How to select patients for liver transplantation?. <i>Journal of Hepatology</i> , 2007, 47, 460-466.	3.7	290

#	ARTICLE	IF	CITATIONS
37	Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. <i>Gastroenterology</i> , 2017, 152, 880-894.e6.	1.3	290
38	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. <i>Lancet Oncology</i> , The, 2018, 19, 682-693.	10.7	285
39	Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. <i>British Journal of Cancer</i> , 2019, 120, 165-171.	6.4	279
40	Liver transplantation for "every early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. <i>Hepatology</i> , 2016, 64, 1178-1188.	7.3	262
41	The EASL "Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet</i> , The, 2022, 399, 61-116.	13.7	257
42	Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib. <i>Clinical Cancer Research</i> , 2012, 18, 4997-5007.	7.0	251
43	Liver Transplantation for Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2008, 15, 1001-1007.	1.5	249
44	Massive parallel sequencing uncovers actionable FGFR2 "PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. <i>Nature Communications</i> , 2015, 6, 6087.	12.8	240
45	Liver cancer: Approaching a personalized care. <i>Journal of Hepatology</i> , 2015, 62, S144-S156.	3.7	239
46	Efficacy of Liver Transplantation in Patients with Primary Biliary Cirrhosis. <i>New England Journal of Medicine</i> , 1989, 320, 1709-1713.	27.0	235
47	Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study. <i>European Journal of Cancer</i> , 2013, 49, 3412-3419.	2.8	218
48	COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 532-533.	8.1	217
49	IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockade. <i>Journal of Hepatology</i> , 2010, 52, 550-559.	3.7	211
50	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. <i>Journal of Hepatology</i> , 2009, 51, 725-733.	3.7	206
51	MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a. <i>Gastroenterology</i> , 2011, 140, 1618-1628.e16.	1.3	205
52	Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. <i>Clinical Cancer Research</i> , 2003, 9, 3235-45.	7.0	197
53	Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. <i>Gut</i> , 2019, 68, 1065-1075.	12.1	195
54	Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 291-300.	7.0	185

#	ARTICLE	IF	CITATIONS
55	Liver resection and transplantation for intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2020, 72, 364-377.	3.7	177
56	Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 947-956.	10.7	166
57	The Place of Liver Transplantation in the Treatment of Hepatic Epitheloid Hemangioendothelioma. <i>Annals of Surgery</i> , 2007, 246, 949-957.	4.2	165
58	A Multistep, Consensus-Based Approach to Organ Allocation in Liver Transplantation: Toward a "Blended Principle Model". <i>American Journal of Transplantation</i> , 2015, 15, 2552-2561.	4.7	164
59	First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1696-1707.	9.4	157
60	Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives. <i>Hepatology</i> , 2013, 58, 2188-2197.	7.3	154
61	The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. <i>American Journal of Transplantation</i> , 2016, 16, 2892-2902.	4.7	151
62	Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. <i>Gut</i> , 2019, 68, 130-139.	12.1	150
63	A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. <i>BMC Cancer</i> , 2010, 10, 190.	2.6	146
64	Massive APOBEC3 Editing of Hepatitis B Viral DNA in Cirrhosis. <i>PLoS Pathogens</i> , 2010, 6, e1000928.	4.7	145
65	Chordoma: Natural history and treatment results in 33 cases. <i>Journal of Surgical Oncology</i> , 1988, 37, 185-191.	1.7	143
66	Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 1998, 5, 29-34.	2.0	137
67	The effect of estrogen and tamoxifen on hepatocyte proliferation in Vivo and in Vitro. <i>Hepatology</i> , 1989, 9, 614-620.	7.3	136
68	Gene-expression signature of vascular invasion in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2011, 55, 1325-1331.	3.7	133
69	Propensity score analysis of outcomes following laparoscopic or open liver resection for hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2016, 103, 871-880.	0.3	130
70	Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: A case-control study. <i>Journal of Hepatology</i> , 2013, 59, 59-66.	3.7	128
71	Radioembolization of hepatocarcinoma with 90Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1718-1738.	6.4	128
72	Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. <i>Transplantation Proceedings</i> , 2001, 33, 1355-1357.	0.6	127

#	ARTICLE	IF	CITATIONS
73	Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2018, 268, 868-875.	4.2	127
74	Human Tumor-Derived Heat Shock Protein 96 Mediates In Vitro Activation and In Vivo Expansion of Melanoma- and Colon Carcinoma-Specific T Cells. <i>Journal of Immunology</i> , 2003, 171, 3467-3474.	0.8	116
75	Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 227-233.	4.2	116
76	Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: Effect of liver transplantation. <i>Hepatology</i> , 2000, 31, 694-703.	7.3	114
77	CHILDBEARING AFTER LIVER TRANSPLANTATION. <i>Transplantation</i> , 1990, 49, 317-320.	1.0	112
78	Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach. <i>Hepatology</i> , 2016, 63, 1707-1717.	7.3	110
79	Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. <i>Journal of Hepatology</i> , 2012, 56, 1080-1088.	3.7	109
80	Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 148, 806-818.e10.	1.3	109
81	Split and whole liver transplantation outcomes: A comparative cohort study. <i>Liver Transplantation</i> , 2006, 12, 402-410.	2.4	106
82	Hierarchic Interaction of Factors Associated With Liver Decompensation After Resection for Hepatocellular Carcinoma. <i>JAMA Surgery</i> , 2016, 151, 846.	4.3	106
83	Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 75-84.	3.7	105
84	Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. <i>Transplantation</i> , 2020, 104, 1136-1142.	1.0	105
85	Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 55, 168-97.	0.7	101
86	Liver transplantation in patients with previous portasystemic shunt. <i>American Journal of Surgery</i> , 1990, 160, 111-116.	1.8	100
87	Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. <i>Journal of Hepatology</i> , 2018, 68, 724-732.	3.7	100
88	Regulation of glucose homeostasis in humans with denervated livers.. <i>Journal of Clinical Investigation</i> , 1997, 100, 931-941.	8.2	95
89	Resection versus transplantation for liver metastases from neuroendocrine tumors. <i>Transplantation Proceedings</i> , 2001, 33, 1537-1539.	0.6	93
90	Extracellular vesicles enhance the targeted delivery of immunogenic oncolytic adenovirus and paclitaxel in immunocompetent mice. <i>Journal of Controlled Release</i> , 2019, 294, 165-175.	9.9	93

#	ARTICLE	IF	CITATIONS
91	Chemoembolization of hepatocellular carcinoma in patients who undergo liver transplantation.. Radiology, 1994, 192, 687-690.	7.3	92
92	Prophylaxis against HCV recurrence after liver transplantation: Effect of interferon and ribavirin combination. Transplantation Proceedings, 1997, 29, 519-521.	0.6	92
93	<i>Helicobacter</i> species sequences in liver samples from patients with and without hepatocellular carcinoma. World Journal of Gastroenterology, 2004, 10, 598.	3.3	92
94	Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut, 2023, 72, 129-140.	12.1	90
95	A clinicopathologic study of primary hepatic carcinoid tumors. Cancer, 1990, 65, 1211-1218.	4.1	88
96	Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 223-230.	6.4	88
97	Balancing Donor and Recipient Risk Factors in Liver Transplantation: The Value of D-MELD With Particular Reference to HCV Recipients. American Journal of Transplantation, 2011, 11, 2724-2736.	4.7	86
98	mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors. Annals of Surgery, 2020, 272, 855-862.	4.2	85
99	HEPATOTROPIC EFFECTS OF FK506 IN DOGS. Transplantation, 1991, 51, 67-69.	1.0	82
100	A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group. Annals of Oncology, 1995, 6, 77-79.	1.2	82
101	Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: A proof of principle. Journal of Hepatology, 2010, 52, 771-775.	3.7	82
102	Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transplantation, 2005, 11, 532-538.	2.4	78
103	Liver transplantation for neuroendocrine tumour liver metastases. Hpb, 2015, 17, 23-28.	0.3	78
104	Laparoscopic and open liver resection for hepatocellular carcinoma with Childâ€™Pugh B cirrhosis: multicentre propensity score-matched study. British Journal of Surgery, 2021, 108, 196-204.	0.3	76
105	Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. Journal of Hepatology, 2007, 46, 645-654.	3.7	75
106	Hepatic Epithelioid Hemangioendothelioma and Adult Liver Transplantation: Proposal for a Prognostic Score Based on the Analysis of the ELTR-ELITA Registry. Transplantation, 2017, 101, 555-564.	1.0	75
107	Systemic Administration and Targeted Delivery of Immunogenic Oncolytic Adenovirus Encapsulated in Extracellular Vesicles for Cancer Therapies. Viruses, 2018, 10, 558.	3.3	73
108	Drugâ€™eluting beads <i>versus</i> conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 645-653.	2.8	71

#	ARTICLE	IF	CITATIONS
109	Strict Selection Alone of Patients Undergoing Liver Transplantation for Hilar Cholangiocarcinoma Is Associated with Improved Survival. <i>PLoS ONE</i> , 2016, 11, e0156127.	2.5	70
110	Liver Match, a prospective observational cohort study on liver transplantation in Italy: Study design and current practice of donor-recipient matching. <i>Digestive and Liver Disease</i> , 2011, 43, 155-164.	0.9	69
111	Transplantation of the liver for metastatic endocrine tumors of the intestine and pancreas. <i>Surgery, Gynecology &amp; Obstetrics</i> , 1989, 168, 107-111.	0.6	68
112	Development and Validation of a Comprehensive Model to Estimate Early Allograft Failure Among Patients Requiring Early Liver Re transplant. <i>JAMA Surgery</i> , 2020, 155, e204095.	4.3	67
113	Percutaneous Transhepatic Biliary Drainage in the Management of Postsurgical Biliary Leaks in Patients with Nondilated Intrahepatic Bile Ducts. <i>CardioVascular and Interventional Radiology</i> , 2006, 29, 380-388.	2.0	66
114	Results of liver transplantation: With or without milan criteria?. <i>Liver Transplantation</i> , 2007, 13, S44-S47.	2.4	66
115	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.. , 2021, 9, e003311.		66
116	Nonhepatic glucose production in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 286, E129-E135.	3.5	64
117	Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation. <i>Journal of Hepatology</i> , 2015, 63, 1368-1377.	3.7	64
118	Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>RAS</i> -Mutated Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 4650-4661.	7.0	63
119	Metabolic effects of successful intraportal islet transplantation in insulin-dependent diabetes mellitus.. <i>Journal of Clinical Investigation</i> , 1996, 97, 2611-2618.	8.2	63
120	Heat Shock Proteins and Their Use as Anticancer Vaccines. <i>Clinical Cancer Research</i> , 2004, 10, 8142-8146.	7.0	62
121	Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. <i>British Journal of Cancer</i> , 2019, 121, 340-343.	6.4	62
122	Early Hepatocellular Carcinoma on the Procrustean Bed of Ablation, Resection, and Transplantation. <i>Seminars in Liver Disease</i> , 2014, 34, 415-426.	3.6	60
123	Impact of home enteral nutrition in malnourished patients with upper gastrointestinal cancer: A multicentre randomised clinical trial. <i>European Journal of Cancer</i> , 2016, 64, 107-112.	2.8	60
124	Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 3176-3184.	4.7	60
125	Occurrence of cytomegalovirus hepatitis in liver transplant patients. <i>Journal of Medical Virology</i> , 1988, 24, 423-434.	5.0	59
126	Importance of early nutritional screening in patients with gastric cancer. <i>British Journal of Nutrition</i> , 2011, 106, 1773-1778.	2.3	59



#	ARTICLE	IF	CITATIONS
127	Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. <i>Annals of Oncology</i> , 2014, 25, 1597-1603.	1.2	59
128	When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. <i>Hpb</i> , 2015, 17, 17-22.	0.3	59
129	Transarterial Chemoembolization for Hepatocellular Carcinoma with a New Generation of Beads: Clinical Radiological Outcomes and Safety Profile. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 129-134.	2.0	59
130	Hormonal and enzymatic parameters of hepatic regeneration in patients undergoing major liver resections. <i>Hepatology</i> , 1990, 12, 1134-1138.	7.3	58
131	Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 173-185.	3.0	57
132	Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. <i>Oncotarget</i> , 2016, 7, 72343-72355.	1.8	57
133	Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study11Data management by Italian Trials in Medical Oncology (I.T.M.O.) Scientific Service.. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 45, 285-289.	0.8	56
134	Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. <i>PLoS ONE</i> , 2016, 11, e0151662.	2.5	56
135	Importance of primary indication and liver function between stages: results of a multicenter Italian audit of ALPPS 2012-2014. <i>Hpb</i> , 2016, 18, 419-427.	0.3	56
136	Evidence of Distinct Tumour-Propagating Cell Populations with Different Properties in Primary Human Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2011, 6, e21369.	2.5	56
137	Hepatocellular carcinoma in patients who undergo liver transplantation: sensitivity of CT with iodized oil.. <i>Radiology</i> , 1997, 203, 457-460.	7.3	55
138	Liver transplantation for small hepatocellular carcinoma in cirrhosis: analysis of our experience. <i>Transplantation Proceedings</i> , 2001, 33, 1442-1444.	0.6	55
139	Donor safety in living donor liver donation: An Italian multicenter survey. <i>Liver Transplantation</i> , 2017, 23, 184-193.	2.4	55
140	Experience with radiofrequency ablation of small hepatocellular carcinomas before liver transplantation. <i>Transplantation Proceedings</i> , 2001, 33, 1516-1517.	0.6	54
141	Toward a Better Liver Graft Allocation That Accounts for Candidates With and Without Hepatocellular Carcinoma. <i>American Journal of Transplantation</i> , 2014, 14, 2221-2227.	4.7	54
142	pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma. <i>Oncolmmunology</i> , 2018, 7, e1445452.	4.6	54
143	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , 2018, 155, 479-489.e7.	1.3	54
144	Duodenal Fistula after Elective Gastrectomy for Malignant Disease. <i>Journal of Gastrointestinal Surgery</i> , 2010, 14, 805-811.	1.7	53

#	ARTICLE	IF	CITATIONS
145	A Prospective Policy Development to Increase Split-Liver Transplantation for 2 Adult Recipients. <i>Annals of Surgery</i> , 2014, 259, 157-165.	4.2	53
146	Effect of age on survival in patients undergoing resection of hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2016, 103, e93-e99.	0.3	53
147	A national mandatory-split liver policy: A report from the Italian experience. <i>American Journal of Transplantation</i> , 2019, 19, 2029-2043.	4.7	52
148	Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: A review and consensus statement. <i>Liver Transplantation</i> , 2011, 17, S81-S89.	2.4	51
149	Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver. <i>European Journal of Surgical Oncology</i> , 2017, 43, 380-387.	1.0	51
150	Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2008, 653, 6-13.	1.7	50
151	Quantitation of estrogen and androgen receptors in hepatocellular carcinoma and adjacent normal human liver. <i>Digestive Diseases and Sciences</i> , 1991, 36, 1303-1308.	2.3	49
152	Liver transplantation for unresectable hepatocellular carcinoma in normal livers. <i>Journal of Hepatology</i> , 2012, 57, 297-305.	3.7	49
153	Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant. <i>Journal of Hepatology</i> , 2020, 73, 342-348.	3.7	49
154	Heterologous and cross-species tropism of cancer-derived extracellular vesicles. <i>Theranostics</i> , 2019, 9, 5681-5693.	10.0	48
155	Natural Killer and NK-Like T-Cell Activation in Colorectal Carcinoma Patients Treated with Autologous Tumor-Derived Heat Shock Protein 96. <i>Cancer Research</i> , 2005, 65, 3942-3949.	0.9	47
156	Estradiol and testosterone levels in patients undergoing partial hepatectomy. <i>Digestive Diseases and Sciences</i> , 1989, 34, 818-822.	2.3	45
157	The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis. <i>Transplant International</i> , 2010, 23, 712-722.	1.6	45
158	Metabolic effects of liver transplantation in cirrhotic patients.. <i>Journal of Clinical Investigation</i> , 1997, 99, 692-700.	8.2	45
159	Vascular invasion and survival after liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry. <i>Hpb</i> , 2018, 20, 768-775.	0.3	44
160	Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion – a multi-center retrospective cohort study. <i>Transplant International</i> , 2020, 33, 567-575.	1.6	44
161	Radioembolization of hepatocarcinoma with 90Y glass microspheres: treatment optimization using the dose-toxicity relationship. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3018-3032.	6.4	44
162	DNA Methylation Profiling of Human Hepatocarcinogenesis. <i>Hepatology</i> , 2021, 74, 183-199.	7.3	42

#	ARTICLE	IF	CITATIONS
163	A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2012, 56, 503-8.	0.7	42
164	Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut, 2023, 72, 736-748.	12.1	42
165	Prolongation of Pig-to-Dog Renal Xenograft Survival by Modification of the Inflammatory Mediator Response. Annals of Surgery, 1987, 206, 482-495.	4.2	41
166	Resting energy expenditure in diabetic and nondiabetic patients with liver cirrhosis: relation with insulin sensitivity and effect of liver transplantation and immunosuppressive therapy. American Journal of Clinical Nutrition, 2002, 76, 541-548.	4.7	41
167	Prognostic Role of Pancreatic Metastases From Renal Cell Carcinoma: Results From an Italian Center. Clinical Genitourinary Cancer, 2013, 11, 484-488.	1.9	41
168	Liver transplantation for adenomatosis: European experience. Liver Transplantation, 2016, 22, 516-526.	2.4	41
169	Locoregional treatments before liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry. Transplant International, 2018, 31, 531-539.	1.6	41
170	The chances of hepatic resection curing hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 711-717.	3.7	41
171	Laparoscopic liver resection of hepatocellular carcinoma located in unfavorable segments: a propensity score-matched analysis from the I Go MILS (Italian Group of Minimally Invasive Liver) Trial. JAMA Network Open, 2023, 6, e230747.	1.4	40
172	The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future. Hepatobiliary Surgery and Nutrition, 2018, 7, 487-489.	1.5	39
173	Fibroblastic reticular cell tumor of the spleen: report of a case and review of the entity. Human Pathology, 2003, 34, 954-957.	2.0	38
174	Factors responsible for hepatic artery thrombosis after pediatric liver transplantation. Transplantation Proceedings, 1989, 21, 2466-7.	0.6	38
175	Living donor liver transplantation for hepatocellular carcinoma exceeding conventional criteria: Questions, answers and demands for a common language. Liver Transplantation, 2006, 12, 896-898.	2.4	36
176	Partial hepatectomy versus radiofrequency ablation for hepatocellular carcinoma: Confirming the trial that will never be, and some comments on the indications for liver resection. Hepatology, 2010, 51, 1116-1118.	7.3	36
177	Effect of TT Virus Infection on Hepatocellular Carcinoma Development: Results of a Euro-Asian Survey. Journal of Infectious Diseases, 2000, 181, 1138-1142.	4.0	35
178	Solid-pseudopapillary tumor of the pancreas (Frantz tumor) in children. Medical and Pediatric Oncology, 2003, 41, 74-76.	1.0	35
179	Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma. Clinical Cancer Research, 2020, 26, 6350-6361.	7.0	35
180	Pharmacologic Modulation of Experimental Postischemic Hepatic Function. Annals of Surgery, 1989, 209, 200-210.	4.2	34

#	ARTICLE	IF	CITATIONS
181	The Italian Consensus on minimally invasive simultaneous resections for synchronous liver metastasis and primary colorectal cancer: A Delphi methodology. <i>Updates in Surgery</i> , 2021, 73, 1247-1265.	2.0	33
182	Transplant Oncology in Primary and Metastatic Liver Tumors. <i>Annals of Surgery</i> , 2021, 273, 483-493.	4.2	33
183	Reappraisal of surgical treatment of small hepatocellular carcinomas in cirrhosis: Clinicopathological study of resection or transplantation. <i>Digestive Diseases and Sciences</i> , 1989, 34, 1571-1575.	2.3	31
184	Primary lymphoma of the liver showing immunohistochemical evidence of T-cell origin. <i>Digestive Diseases and Sciences</i> , 1988, 33, 1632-1636.	2.3	30
185	Current challenges in liver transplantation for hepatocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 867-879.	2.4	30
186	Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes. <i>Future Oncology</i> , 2016, 12, 1251-1260.	2.4	29
187	Microenvironment and tumor inflammatory features improve prognostic prediction in gastroenteropancreatic neuroendocrine neoplasms. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 217-226.	3.0	29
188	Risk-adjusted benchmarks in laparoscopic liver surgery in a national cohort. <i>British Journal of Surgery</i> , 2020, 107, 845-853.	0.3	29
189	Further steps of hepatic stimulatory substance purification. <i>Digestive Diseases and Sciences</i> , 1991, 36, 674-680.	2.3	28
190	Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma. <i>Liver International</i> , 2016, 36, 1033-1042.	3.9	28
191	hepatic arterial embolization with microencapsulated mitomycin C for unresectable hepatocellular carcinoma in cirrhosis. <i>Cancer</i> , 1990, 66, 228-236.	4.1	26
192	The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: Pros and cons. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 473-483.	5.7	26
193	FK 506 as a growth control factor. <i>Transplantation Proceedings</i> , 1990, 22, 90-2.	0.6	26
194	The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 634-638.	6.4	25
195	Permanent Pancreatic Duct Occlusion With Neoprene-based Glue Injection After Pancreatoduodenectomy at High Risk of Pancreatic Fistula. <i>Annals of Surgery</i> , 2019, 270, 791-798.	4.2	25
196	Transarterial chemoembolization using 40 $\mu$ m drug eluting beads for hepatocellular carcinoma. <i>World Journal of Radiology</i> , 2017, 9, 245.	1.1	25
197	8. Multidisciplinary Approach for the Treatment of Neuroendocrine Tumors. <i>Tumori</i> , 2010, 96, 833-846.	1.1	24
198	Principles for the best multidisciplinary meetings. <i>Lancet Oncology</i> , The, 2011, 12, 323-325.	10.7	24

#	ARTICLE	IF	CITATIONS
199	Endoscopic ultrasound-guided esophagoenterostomy for a completely obstructed surgical anastomosis. <i>Endoscopy</i> , 2016, 48, E1-E2.	1.8	24
200	Surgical management of duodenal stump fistula after elective gastrectomy for malignancy: an Italian retrospective multicenter study. <i>Gastric Cancer</i> , 2016, 19, 273-279.	5.3	24
201	Pro (With Caution): Extended oncologic indications in liver transplantation. <i>Liver Transplantation</i> , 2018, 24, 98-103.	2.4	24
202	Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation. <i>Hpb</i> , 2019, 21, 731-738.	0.3	24
203	Risk of HBV reinfection after liver transplantation in HBsAg-positive cirrhosis: Primary hepatocellular carcinoma is not a predictor for HBV recurrence. <i>Liver</i> , 1996, 16, 117-122.	0.1	22
204	Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. <i>Medical Oncology</i> , 2015, 32, 182.	2.5	22
205	Surgical resection for hepatocellular carcinoma: Moving from what can be done to what is worth doing. <i>Hepatology</i> , 2015, 62, 340-342.	7.3	22
206	Liver Replantation in Adults: The Largest Multicenter Italian Study. <i>PLoS ONE</i> , 2012, 7, e46643.	2.5	22
207	Intrahepatic Flow Redistribution in Patients Treated with Radioembolization. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 322-328.	2.0	21
208	A matched pair analysis of multicenter longterm follow-up after split-liver transplantation with extended right grafts. <i>Liver Transplantation</i> , 2017, 23, 1384-1395.	2.4	21
209	Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2017, 104, 1704-1712.	0.3	21
210	Thoracic paravertebral anesthesia for percutaneous radiofrequency ablation of hepatic tumors. <i>Journal of Clinical Anesthesia</i> , 2014, 26, 271-275.	1.6	20
211	Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). <i>International Journal of Cancer</i> , 2019, 144, 1704-1712.	5.1	20
212	Ewing sarcoma of the small bowel: a study of seven cases, including one with the uncommonly reported EWSR1- <i>FEV</i> translocation. <i>Histopathology</i> , 2014, 64, 1014-1026.	2.9	19
213	The role of lymphadenectomy in the surgical treatment of intrahepatic cholangiocarcinoma: A review. <i>European Journal of Surgical Oncology</i> , 2022, 48, 150-159.	1.0	19
214	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. <i>Liver Transplantation</i> , 2021, 27, 1767-1778.	2.4	19
215	Renal artery reconstruction for harvesting injuries in kidney transplantation with particular reference to the use of vascular allografts. <i>Transplant International</i> , 1988, 1, 80-85.	1.6	18
216	A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study. <i>Digestive and Liver Disease</i> , 2014, 46, 340-347.	0.9	18

#	ARTICLE	IF	CITATIONS
217	Repeated transarterial chemoembolization: An overfitting effort?. <i>Journal of Hepatology</i> , 2015, 62, 1440-1442.	3.7	18
218	Endoatherapies for biliary ductto duct anastomotic stricture after liver transplantation: Outcomes of a nationwide survey. <i>Liver International</i> , 2019, 39, 1355-1362.	3.9	18
219	Multicentre evaluation of case volume in minimally invasive hepatectomy. <i>British Journal of Surgery</i> , 2020, 107, 443-451.	0.3	18
220	Feasibility of Peritonectomy Associated with Intraperitoneal Hyperthermic Perfusion in Patients with Pseudomyxoma Peritonei. <i>Tumori</i> , 2002, 88, 370-375.	1.1	17
221	Thyroid as a Target of Metastases. A Case of Foregut Neuroendocrine Carcinoma with Multiple Abdominal Metastases and a Thyroid Localization after 21 Years. <i>Tumori</i> , 2008, 94, 110-113.	1.1	17
222	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. <i>British Journal of Cancer</i> , 2018, 118, 955-965.	6.4	17
223	Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma. <i>American Journal of Pathology</i> , 2019, 189, 2090-2101.	3.8	17
224	Response and relapse rates after treatment with longacting somatostatin analogs in multifocal or recurrent type1 gastric carcinoids: A systematic review and metaanalysis. <i>United European Gastroenterology Journal</i> , 2020, 8, 140-147.	3.8	17
225	Studies of the hepatotropic qualities of FK 506 and CyA. <i>Transplantation Proceedings</i> , 1990, 22, 93-5.	0.6	17
226	Resection, transplantation, either, or both? Other pieces of the puzzle. <i>Liver Transplantation</i> , 2005, 11, 1177-1180.	2.4	16
227	Dissecting EASL/AASLD Recommendations With a More Careful Knife. <i>Annals of Surgery</i> , 2015, 262, e17-e18.	4.2	16
228	Management of biliary anastomotic strictures after liver transplantation (BASALT study): A nationwide Italian survey. <i>Liver Transplantation</i> , 2017, 23, 257-261.	2.4	16
229	A Combined Approach to Priorities of Surgical Oncology During the COVID-19 Epidemic. <i>Annals of Surgery</i> , 2020, 272, e84-e86.	4.2	16
230	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. <i>Clinical Colorectal Cancer</i> , 2020, 19, 156-164.	2.3	16
231	Prognostic factors in patients affected by hepatocellular carcinoma treated with systemic chemotherapy: The experience of the National Cancer Institute of Milan. <i>Annals of Oncology</i> , 1993, 4, 489-493.	1.2	15
232	Assessment of insulin sensitivity based on a fasting blood sample in men with liver cirrhosis before and after liver transplantation1. <i>Transplantation</i> , 2003, 76, 697-702.	1.0	15
233	First-Line Treatment for Hepatocellular Carcinoma: Resection or Transplantation?. <i>Transplantation Proceedings</i> , 2007, 39, 2271-2273.	0.6	15
234	Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis. <i>BMC Cancer</i> , 2018, 18, 715.	2.6	15

#	ARTICLE	IF	CITATIONS
235	RECURRENCE OF DESMOID TUMOR IN A MULTIVISCERAL TRANSPLANT PATIENT WITH GARDNER'S SYNDROME. <i>Transplantation</i> , 1999, 67, 1197-1199.	1.0	15
236	Renal artery reconstruction for harvesting injuries in kidney transplantation with particular reference to the use of vascular allografts. <i>Transplant International</i> , 1988, 1, 80-85.	1.6	14
237	The Role of Somatostatin Analogues in the Treatment of Gastro-Enteropancreatic Endocrine Tumours. <i>Digestion</i> , 1996, 57, 72-76.	2.3	14
238	Ki-67 and presence of liver metastases identify different progression-risk classes in pancreatic neuroendocrine neoplasms (pNEN) undergoing resection. <i>European Journal of Surgical Oncology</i> , 2019, 45, 755-760.	1.0	14
239	Proposal of Prognostic Survival Models before and after Liver Resection for Hepatocellular Carcinoma in Potentially Transplantable Patients. <i>Journal of the American College of Surgeons</i> , 2018, 226, 1147-1159.	0.5	13
240	Minimally Invasive Stage 1 to Protect Against the Risk of Liver Failure: Results from the Hepatocellular Carcinoma Series of the Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy Italian Registry. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2020, 30, 1082-1089.	1.0	13
241	Postrecurrence Survival After Liver Transplantation for Liver Metastases From Neuroendocrine Tumors. <i>Transplantation</i> , 2021, 105, 2579-2586.	1.0	13
242	Cancer-derived EVs show tropism for tissues at early stage of neoplastic transformation. <i>Nanotheranostics</i> , 2021, 5, 1-7.	5.2	13
243	Kaposi's sarcoma: Malignant tumor or proliferative disorder?. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1988, 24, 973-978.	0.7	12
244	Immunocytochemical Detection and Characterization of Intrahepatic Human Pancreatic Islets after Combined Liver-Islet Allograft Transplantation. <i>Cell Transplantation</i> , 1994, 3, 499-508.	2.5	12
245	Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2017, 16, e191-e198.	2.3	12
246	A Longitudinal Investigation of Posttraumatic Growth and Quality of Life in Liver Transplant Recipients. <i>Progress in Transplantation</i> , 2018, 28, 236-243.	0.7	12
247	Multidisciplinary approach for the treatment of neuroendocrine tumors. <i>Tumori</i> , 2010, 96, 833-46.	1.1	12
248	Mutation and transcription analysis of transthyretin gene in Italian families with hereditary amyloidosis: a putative novel "hot spot" in codon 47. <i>Clinical Genetics</i> , 2001, 57, 284-290.	2.0	11
249	Assessing Competing Risks for Death Following Liver Transplantation for Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1001-1007.	2.3	11
250	Radioembolization of Hepatocellular Carcinoma with 90Y Glass Microspheres: No Advantage of Voxel Dosimetry with Respect to Mean Dose in Dose-Response Analysis with Two Radiological Methods. <i>Cancers</i> , 2022, 14, 959.	3.7	11
251	Amino Acid Kinetics During the Anhepatic Phase of Liver Transplantation. <i>Diabetes</i> , 2002, 51, 1690-1698.	0.6	10
252	CT cholangiography: Assessment of feasibility and diagnostic reliability. <i>European Journal of Radiology</i> , 2009, 72, 114-117.	2.6	10

#	ARTICLE	IF	CITATIONS
253	Transhepatic anterior approach to the inferior vena cava in large retroperitoneal tumors resected en bloc with the right liver lobe. <i>Surgery</i> , 2013, 154, 1061-1068.	1.9	10
254	Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy. <i>Liver International</i> , 2017, 37, 678-683.	3.9	10
255	Preoperative predictors of liver decompensation after mini-invasive liver resection. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 718-727.	2.4	10
256	Liver resection for perihilar cholangiocarcinoma: Impact of biliary drainage failure on postoperative outcome. Results of an Italian multicenter study. <i>Surgery</i> , 2021, 170, 383-389.	1.9	10
257	Is minimally invasive liver surgery a reasonable option in recurrent HCC? A snapshot from the I Go MILS registry. <i>Updates in Surgery</i> , 2022, 74, 87-96.	2.0	10
258	Impact of Surgical Margins on Overall Survival after Gastrectomy for Gastric Cancer: A Validation of Japanese Gastric Cancer Association Guidelines on a Western Series. <i>Annals of Surgical Oncology</i> , 2022, 29, 3096-3108.	1.5	10
259	Candidates for liver transplantation for cancer: physical, psychological, and social conditions. <i>Transplantation</i> , 2002, 73, 1627-1635.	1.0	9
260	Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review. <i>Future Oncology</i> , 2015, 11, 1947-1959.	2.4	9
261	Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study. <i>Cancers</i> , 2022, 14, 69.	3.7	9
262	Simultaneous characterization of progenitor cell compartments in adult human liver. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2010, 77A, 31-40.	1.5	8
263	Expert opinion on advanced techniques for hemostasis in liver surgery. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1597-1607.	1.0	8
264	Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors. <i>Endocrine</i> , 2017, 57, 512-517.	2.3	8
265	Alpha-fetoprotein in liver transplantation for hepatocellular carcinoma: The lower, the better. <i>Hepatology</i> , 2018, 68, 775-777.	7.3	8
266	Mortality after Transplantation for Hepatocellular Carcinoma: A Study from the European Liver Transplant Registry. <i>Liver Cancer</i> , 2020, 9, 455-467.	7.7	8
267	Combined immunotherapy and VEGF-antagonist in hepatocellular carcinoma: a step forward. <i>Lancet Oncology</i> , The, 2020, 21, 740-741.	10.7	8
268	Thrombosis after liver transplantation for hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0186699.	2.5	8
269	Confirmation of graft-versus-host disease after liver transplantation by PCR HLA-typing. <i>Transplantation</i> , 1993, 55, 423-5.	1.0	8
270	Effect of cyclosporine on hepatic energy status and on fructose metabolism after portacaval shunt in dog as monitored by phosphorus-31 nuclear magnetic resonance spectroscopy in vivo. <i>Hepatology</i> , 1991, 13, 780-785.	7.3	7



#	ARTICLE	IF	CITATIONS
271	Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals. <i>Journal of Hepatology</i> , 2017, 67, 415-417.	3.7	7
272	The Italian Rare Pancreatic Exocrine Cancer Initiative. <i>Tumori</i> , 2019, 105, 353-358.	1.1	7
273	Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2019, 18, 34-43.e6.	2.3	7
274	Surgical Management of Hepatic Benign Disease: Have the Number of Liver Resections Increased in the Era of Minimally Invasive Approach? Analysis from the I Go MILS (Italian Group of Minimally Invasive) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.1	7
275	Development of a prognostic scoring system for resectable hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 8194.	3.3	7
276	Pancreaticoduodenectomy in octogenarians: The importance of "biological age" on clinical outcomes. <i>Surgical Oncology</i> , 2022, 40, 101688.	1.6	7
277	Role of estrogens and epidermal growth factor in hepatocellular carcinoma (HCC). <i>Digestive Diseases and Sciences</i> , 1991, 36, 1299-1302.	2.3	6
278	Hepatic resection for hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 1993, 53, 62-66.	1.7	6
279	Preoperative serum levels of wild-type and hepatitis B e antigen-negative hepatitis B virus (HBV) and graft infection after liver transplantation for HBV-related hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 1997, 4, 235-242.	2.0	6
280	Post-absorptive and insulin-mediated muscle protein metabolism in liver-transplanted patients. <i>Acta Diabetologica</i> , 2002, 39, 203-208.	2.5	6
281	ETOPOSIDE, CISPLATIN, EPIRUBICIN CHEMOTHERAPY IN THE TREATMENT OF PEDIATRIC LIVER TUMORS. <i>Pediatric Hematology and Oncology</i> , 2005, 22, 189-198.	0.8	6
282	Succinate Dehydrogenase B Subunit Immunohistochemical Expression Predicts Aggressiveness in Well Differentiated Neuroendocrine Tumors of the Ileum. <i>Cancers</i> , 2012, 4, 808-820.	3.7	6
283	Quantitative assessment of the impact of COVID-19 pandemic on pancreatic surgery: an Italian multicenter analysis of 1423 cases from 10 tertiary referral centers. <i>Updates in Surgery</i> , 2021, , 1.	2.0	6
284	Variations in risk-adjusted outcomes following 4318 laparoscopic liver resections. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2022, 29, 521-530.	2.6	6
285	Bone Lesion in a Patient with Transplanted Liver for a Metastatic Carcinoid. The Role of Somatostatin Receptor Scintigraphy. <i>Tumori</i> , 1998, 84, 82-84.	1.1	5
286	Authors'™ response to the letter: Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours or portal hypertension by Zhong<i>et al</i>. <i>Gut</i> , 2015, 64, 522-522.	12.1	5
287	Combined liver and pancreatic islets transplantation in man using cyclosporin immunosuppression. <i>Transplant International</i> , 1994, 7, 409-411.	1.6	4
288	Psychosocial adaptation after liver transplantation with particularreference to recipients aware of their cancer. <i>European Journal of Surgical Oncology</i> , 1996, 22, 240-244.	1.0	4

#	ARTICLE	IF	CITATIONS
289	94 Prospective randomised trial on IFN-therapy for the secondary prevention of HCC recurrence after curative resection in HCV related cirrhosis. Preliminary report. <i>Journal of Hepatology</i> , 2004, 40, 34.	3.7	4
290	External validation of an individual prognostic calculator after transarterial chemoembolization for hepatocellular carcinoma. <i>Liver International</i> , 2016, 36, 1231-1231.	3.9	4
291	Endoscopic ultrasound-guided fine needle aspiration of splenic vein thrombosis: a novel approach to the portal venous system. <i>Endoscopy</i> , 2016, 48, E40-E41.	1.8	4
292	HCC recurrence in HCV-infected patients after liver transplantation: SiLVER Study reveals benefits of sirolimus in combination with CNIs – a <i>post hoc</i> analysis. <i>Transplant International</i> , 2020, 33, 917-924.	1.6	4
293	Well-differentiated neuroendocrine tumor of tailgut cyst. A rare entity with controversial medical opportunities. <i>Tumori</i> , 2013, 99, e148-51.	1.1	4
294	Milan multicenter experience in liver transplantation for hepatitis C-related cirrhosis: report of 105 cases. <i>Transplantation Proceedings</i> , 1994, 26, 3582-4.	0.6	4
295	Cyclosporine and liver regeneration studied by in vivo <sup>31</sup> P nuclear magnetic resonance spectroscopy. <i>Digestive Diseases and Sciences</i> , 1991, 36, 687-692.	2.3	3
296	Reappraisal of the role of liver transplantation in the treatment of hepatocellular carcinoma arising in cirrhosis. <i>Journal of Surgical Oncology</i> , 1993, 53, 83-86.	1.7	3
297	Renal-splenic shunt for infrahepatic caval occlusion after piggy-back liver transplantation. <i>Transplant International</i> , 1997, 10, 392-394.	1.6	3
298	Renal-splenic shunt for intrahepatic caval occlusion after piggy-back liver transplantation. <i>Transplant International</i> , 1997, 10, 392-394.	1.6	3
299	Increased Retinol Binding Protein in the Sera of Patients with Severe Ischemic Damage of the Liver after Transplantation. <i>Clinical Biochemistry</i> , 1998, 31, 113-116.	1.9	3
300	Transthyretin RNA profiling in livers from transplanted patients affected by familial amyloidotic polyneuropathy, and identification of a dual transcription start point. <i>Liver International</i> , 2006, 26, 211-220.	3.9	3
301	Phenomenology and Emotional Impact of Neuropsychiatric Symptoms in Orthotopic Liver Transplant for Hepatocellular Carcinoma. <i>Transplantation Proceedings</i> , 2007, 39, 1564-1568.	0.6	3
302	Multiagent imaging of liver tumors with reference to intra-arterial radioembolization. <i>Clinical and Translational Imaging</i> , 2013, 1, 423-432.	2.1	3
303	Hepatocellular Carcinoma in Abernethy Malformation: A Rare Occurrence of Congenital Complete Portosystemic Shunt. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1775-1778.	0.5	3
304	Comparison Between Swan-Ganz Catheter and Minimally Invasive Hemodynamic Monitoring During Liver Transplantation: Report of a Monocentric Case Series. <i>Transplantation Proceedings</i> , 2019, 51, 2943-2947.	0.6	3
305	Resection of Retro-Hepatic Vena Cava (RHVC) En-bloc with Caudate Lobe without Vascular Exclusion for a Low Grade Leiomyosarcoma of Inferior Vena Cava. <i>Annals of Surgical Oncology</i> , 2021, 28, 6848-6849.	1.5	3
306	Inter-center agreement of mRECIST in transplanted patients for hepatocellular carcinoma. <i>European Radiology</i> , 2021, 31, 8903-8912.	4.5	3

#	ARTICLE	IF	CITATIONS
307	Migration rate using Fullyâ€covered metal stent in anastomotic strictures after liver transplantation: Results from the <sc>BASALT</sc> Study Group. <i>Liver International</i> , 2022, , .	3.9	3
308	Utility of the Iwate difficulty scoring system for laparoscopic right posterior sectionectomy: do surgical outcomes differ for tumors in segments VI and VII?. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 9204-9214.	2.4	3
309	Approach to Hepatic Metastases from Colorectal Adenocarcinoma. <i>Seminars in Liver Disease</i> , 1988, 8, 247-253.	3.6	2
310	A Modified Technique of Orthotopic Transplant of the Kidney in Rabbits. <i>Journal of Investigative Surgery</i> , 1989, 2, 293-303.	1.3	2
311	Effect of liver transplantation in cirrhotic diabetic patients. <i>Transplantation Proceedings</i> , 1998, 30, 1868.	0.6	2
312	Exploiting liver immunity for the prevention of hepatic metastases. <i>Journal of Hepatology</i> , 2010, 53, 596-598.	3.7	2
313	Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma. <i>Liver International</i> , 2015, 35, 2187-2193.	3.9	2
314	Reply. <i>Hepatology</i> , 2016, 63, 1054-1055.	7.3	2
315	Improved management of grade B biliary leaks after complex liver resections using gadoxetic acid disodiumâ€enhanced magnetic resonance cholangiography. <i>Surgery</i> , 2021, 170, 499-506.	1.9	2
316	Acquired Resistance Mechanisms to PD-L1 Blockade in a Patient With Microsatellite Instability-High Extrahepatic Cholangiocarcinoma. <i>JCO Precision Oncology</i> , 2022, 6, e2100472.	3.0	2
317	<sc>MGMT</sc> inactivation as a new biomarker in patients with advanced biliary tract cancers. <i>Molecular Oncology</i> , 2022, 16, 2733-2746.	4.6	2
318	Milan criteria, up-to-seven criteria, and the illusion of a rescue package for patients with liver cancer â€ Authors' reply. <i>Lancet Oncology</i> , The, 2009, 10, 208-209.	10.7	1
319	Reply to: â€Sorafenib efficacy for treatment of HCC recurrence after liver transplantation is an open issueâ€. <i>Journal of Hepatology</i> , 2014, 60, 682-683.	3.7	1
320	Reply to: â€Validation of response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasionâ€. <i>Journal of Hepatology</i> , 2018, 69, 260-261.	3.7	1
321	Reply. <i>Gastroenterology</i> , 2018, 154, 2276-2277.	1.3	1
322	Spontaneous hypoglycaemia after pancreas transplantation in Type 1 diabetes mellitus. <i>Diabetic Medicine</i> , 1998, 15, 991-996.	2.3	1
323	Liver transplantation as last-resort treatment for patients with bile duct injuries following cholecystectomy: a multicenter analysis. <i>Annals of Gastroenterology</i> , 2020, 34, 111-118.	0.6	1
324	ASO Visual Abstract: Impact of Surgical Margins on Overall Survival After Gastrectomy for Gastric Cancer: A Validation of Japanese Gastric Cancer Association Guidelines on a Western Series. <i>Annals of Surgical Oncology</i> , 2022, 29, 3111.	1.5	1

#	ARTICLE	IF	CITATIONS
325	ASO Author Reflections: Less is more: Organ-Sparing Approach for the Surgical Treatment of Gastric Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 3109-3110.	1.5	1
326	Carcinoid syndrome. <i>Pediatric Surgery International</i> , 1996, 11, 398-399.	1.4	0
327	Reply:. <i>Hepatology</i> , 2013, 58, 452-453.	7.3	0
328	Reply to: "Time is a crucial factor for the use of oncological treatment for post-transplantation recurrence of hepatocellular carcinoma". <i>Journal of Hepatology</i> , 2014, 60, 230-231.	3.7	0
329	Relative Survival Instead of Overall Survival Should Be Used as Outcome When Analyzing the Effect of Age After Treatment of Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2018, 268, e76.	4.2	0
330	85. Treatment of hepatocarcinoma with 90Y glass microspheres: Safety and indication of prolonged overall survival thanks to two compartment dosimetric treatment planning. <i>Physica Medica</i> , 2018, 56, 114-115.	0.7	0
331	Clinical Options for Treatment of Hepatocellular Carcinoma. , 2018, , 95-105.		0
332	ASO Author Reflections: Amid Anatomic Restrictions, Three-Dimensional Surgical Planning Eases En Bloc Resection of the Retro-Hepatic Vena Cava and the Caudate Lobe of the Liver. <i>Annals of Surgical Oncology</i> , 2021, 28, 6850-6851.	1.5	0
333	Liver Resection and Transplantation for Metastases from Gastroenteropancreatic Neuroendocrine Tumors. <i>Updates in Surgery Series</i> , 2020, , 221-233.	0.1	0
334	Long Term Survival Analysis in a Cohort of 125 Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using Small Drug Eluting Beads. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 54-61.	2.0	0